Document:

<PAGE>

                                                                    EXHIBIT 10.5

THESE SECURITIES AND THE SECURITIES ISSUABLE UPON THEIR EXERCISE HAVE NOT BEEN
REGISTERED UNDER THE SECURITIES ACT OF 1933 AND MAY NOT BE TRANSFERRED UNLESS
COVERED BY AN EFFECTIVE REGISTRATION STATEMENT UNDER SAID ACT, OR AN OPINION OF
COUNSEL SATISFACTORY TO THE ISSUER TO THE EFFECT THAT ANY SUCH TRANSFER IS
EXEMPT FROM SUCH REGISTRATION.

                               PCSUPPORT.COM, INC.
                                     WARRANT
                        FOR THE PURCHASE OF COMMON STOCK

     1.  Issuance. For value received, the receipt of which is hereby
         --------
acknowledged by PCSupport.com, Inc., a Nevada corporation (the "Company"),
Welcome Opportunities Ltd., or registered assigns (the "Holder"), is hereby
granted the right to purchase, at any time until October 19, 2003 (the
"Expiration Date"), ONE HUNDRED AND SIXTY THOUSAND (160,000) fully paid and
nonassessable shares of the Company's common stock, par value $.001 (the "Common
Stock"), at the exercise price of $0.20 per share (the "Exercise Price").

     2.  Procedure for Exercise. Upon surrender of this Warrant with the annexed
         ----------------------
Notice of Exercise Form duly executed, together with payment of the Exercise
Price for the shares of Common Stock purchased, the Holder shall be entitled to
receive a certificate or certificates for the shares of Common Stock so
purchased.

     3.  Reservation of Shares. The Company hereby agrees that at all times
         ---------------------
during the term of this Warrant there shall be reserved for issuance upon
exercise of this Warrant such number of shares of its Common Stock as shall be
required for issuance upon exercise of this Warrant (the "Warrant Shares").

     4.  Mutilation or Loss of Warrant. Upon receipt by the Company of evidence
         -----------------------------
satisfactory to it of the loss, theft, destruction or mutilation of this
Warrant, and (in the case of loss, theft or destruction) receipt of reasonably
satisfactory indemnification, and (in the case of mutilation) upon surrender and
cancellation of this Warrant, the Company will execute and deliver a new warrant
of like tenor and date and any such lost, stolen, destroyed or mutilated Warrant
shall thereupon become void.

     5.  No Rights as Shareholder. The Holder shall not, by virtue hereof, be
         ------------------------
entitled to any rights of a shareholder of the Company, either at law or in
equity, and the rights of the Holder are limited to those expressed in this
Warrant and are not enforceable against the Company except to the extent set
forth herein.

     6.  Effect of Certain Transactions
         ------------------------------

         6.1  Adjustments for Stock Splits, Stock Dividends Etc. If the number
              -------------------------------------------------
of outstanding shares of Common Stock of the Company are increased or decreased
by a stock split, reverse stock split, stock dividend, stock combination,
recapitalization or the like, the Exercise Price and the number of shares
purchasable pursuant to this Warrant shall be adjusted proportionately so that
the ratio of (i) the aggregate number of shares purchasable by exercise of this
Warrant to (ii) the total number of shares outstanding immediately following
such stock split, reverse stock split, stock dividend, stock combination,
recapitalization or the like shall remain unchanged, and the aggregate purchase
price of shares issuable pursuant to this Warrant shall remain unchanged.

<PAGE>

         6.2  Expiration Upon Certain Transactions. If at any time the Company
              ------------------------------------
engages in a merger or consolidation of the Company in which the Company will
not survive and in which holders of the Company's Common Stock will receive
consideration at or above the Exercise Price, as adjusted, then this Warrant
will terminate 10 days from the Holder's receipt of written notice ("Notice")
from the Company of the completion of such a transaction. The Notice will inform
the Holder that the Warrant will terminate 10 days from the Holder's receipt of
the Notice. The Holder may exercise this Warrant within the 10-day period
pursuant to Section 2.

         6.3  Adjustments for Reorganization, Mergers, Consolidations or Sales
              ----------------------------------------------------------------
of Assets. If at any time there is a capital reorganization of the Common Stock
---------
(other than a recapitalization, combination, or the like provided for elsewhere
in this Section 6) or merger or consolidation of the Company with another
corporation (other than one covered by Section 6.2), or the sale of all or
substantially all of the Company's properties and assets to any other person,
then, as a part of such reorganization, merger, consolidation or sale, provision
shall be made so that the Holder shall thereafter be entitled to receive upon
exercise of this Warrant (and only to the extent this Warrant is exercised), the
number of shares of stock or other securities or property of the Company, or of
the successor corporation resulting from such merger or consolidation or sale,
to which a holder of Common Stock, or other securities, deliverable upon the
exercise of this Warrant would otherwise have been entitled on such capital
reorganization, merger, consolidation or sale. In any such case, appropriate
adjustments shall be made in the application of the provisions of this Section 6
(including adjustment of the Exercise Price then in effect and number of Warrant
Shares purchasable upon exercise of this Warrant) which shall be applicable
after such events.

     7.  Transfer to Comply with the Securities Act. This Warrant has not been
         ------------------------------------------
registered under the Securities Act of 1933, as amended, (the "Securities Act")
and has been issued to the Holder for investment and not with a view to the
distribution of either the Warrant or the Warrant Shares. Neither this Warrant
nor any of the Warrant Shares or any other security issued or upon exercise of
this Warrant may be sold, transferred, pledged or hypothecated in the absence of
an effective registration statement under the Securities Act relating to such
security or an opinion of counsel satisfactory to the Company that registration
is not required under the Act. Each certificate for the Warrant, the Warrant
Shares and any other security issued or issuable upon exercise of this Warrant
shall contain a legend in form and substance satisfactory to counsel for the
Company, setting forth the restrictions on transfer contained in this Section.

     8.  Registration Rights. The Company anticipates closing a private
         -------------------
placement of up to 4,200,000 shares of its common stock at $0.12 per share in
the near future (the "Private Placement"). The Company agrees to offer the
Holder the opportunity to include the Warrant Shares in any registration
statement filed by the Company before October 19, 2002 under the Securities Act
in connection with the registration of common shares issued pursuant to the
Private Placement.

     9.  Notices. Any notice or other communication required or permitted
         -------
hereunder shall be in writing and shall be delivered personally or sent by
certified, registered or express mail, postage pre-paid. Any such notice shall
be deemed given when so delivered personally, or if mailed, two days after the
date of deposit in the United States mails, as follows:

                                       2

<PAGE>

         If to the Company, to:

               PCSupport.com, Inc.
               3605 Gilmore Way, Suite 300
               Burnaby, British Columbia, Canada V5G 4X5
               Attention:  Mike McLean, President

         With a copy to:

               Troy & Gould Professional Corporation
               1801 Century Park East, 16th Floor
               Los Angeles, CA 90067
               Attention:  Sanford J. Hillsberg, Esq.

         If to the Holder, to:

               Welcome Opportunities Ltd.
               1450 Creekside Drive, Suite 800
               Vancouver, British Columbia, V6J 5B3

Any party may designate another address or person for receipt of notices
hereunder by notice given to the other parties in accordance with this Section.

     10. Supplements and Amendments; Whole Agreement. This Warrant may be
         -------------------------------------------
amended or supplemented only by an instrument in writing signed by the parties
hereto. This Warrant contains the full understanding of the parties hereto with
respect to the subject matter hereof, and there are no representations,
warranties, agreements or understandings other than expressly contained herein.

     11. Governing Law. This Warrant shall be deemed to be a contract made under
         -------------
the laws of the Province of British Columbia and for all purposes shall be
governed by and construed in accordance with the laws of such Province
applicable to contracts to be made and performed entirely within such Province.

     12. Counterparts. This Warrant may be executed in any number of
         ------------
counterparts and each of such counterparts shall for all purposes be deemed to
be an original, and all such counterparts shall together constitute but one and
the same instrument.

     13. Descriptive Headings. Descriptive headings of the several Sections of
         --------------------
this Warrant are inserted for convenience only and shall not control or affect
the meaning or construction of any of the provisions hereof.

     14. Assignability. This Warrant or any part thereof may be hereafter
         -------------
assigned by the Holder to any accredited investor executing documents reasonably
required by the Company. Any such assignment shall be binding on the Company and
shall inure to the benefit of any such assignee.

     15. Currency. All references to dollar amounts herein refer to United
         --------
States currency.

                                       3

<PAGE>

         IN WITNESS WHEREOF, the parties hereto have executed this Warrant as of
October 19, 2001.

                                         PCSUPPORT.COM, INC.

                                         By:       /s/ Mike McLean
                                            ------------------------------------

                                         Name:  Mike McLean
                                         Title: President

                                       4

<PAGE>

                          NOTICE OF EXERCISE OF WARRANT

         The undersigned hereby irrevocably elects to exercise the right,
represented by the Warrant dated as of _______________________________ to
purchase _____________ shares of the Common Stock of PCSupport.com, Inc., and
tenders herewith payment in accordance with Section 2 of the Common Stock
Purchase Warrant.

         Please deliver the stock certificate to:

         _____________________________________________
         _____________________________________________
         _____________________________________________

Dated:______________________________

By:_________________________________

                                       5<PAGE>
                                                                    EXHIBIT 10.1

                     LEAD GENERATION COLLABORATION AGREEMENT

     This LEAD GENERATION COLLABORATION AGREEMENT (the "Agreement"), effective
as of July 18, 2001 (the "Effective Date"), is made by and between Array
BioPharma Inc., a Delaware corporation having its principal offices located at
1885 33rd Street, Boulder, CO 80301 ("Array"), and Takeda Chemical Industries,
Ltd., a Japanese corporation having a place of business at 1-1, Doshomachi
4-Chome, Chuo-ku, Osaka 540-8645, Japan ("Takeda").

                                   BACKGROUND

     A.   Array has developed novel, proprietary methods for the discovery,
          generation and optimization of lead compounds;

     B.   Takeda and Array desire to collaborate to identify lead compounds that
          have activity in the Field (as defined below); and

     C.   Takeda wishes to develop and commercialize the Products (as defined
          below) in the Field, on the terms and conditions herein;

     NOW, THEREFORE, for and in consideration of the covenants, conditions and
undertakings hereinafter set forth, it is agreed by and between the parties as
follows:

     1. DEFINITIONS

     As used herein, the following terms will have the meanings set forth below:

     1.1 "Affiliate" shall mean any corporation or other entity which is
directly or indirectly controlling, controlled by or under common control of a
party hereto for so long as such control exists. For the purposes of this
Section 1.1, "control" shall mean the direct or indirect ownership of at least
fifty percent (50%) of the outstanding shares or other voting rights of the
subject entity to elect directors, or if not meeting the preceding the maximum
voting right that may be held by the particular party under the laws of the
country where such entity exists.

     1.2 "Array Technology" shall mean (i) all information, data, know-how,
patents and patent applications that are necessary to conduct the Research
Program, and (ii) any divisions, continuations, continuations-in-part, reissues,
reexaminations, or extensions, thereof and any substitutions, confirmations or
registrations of any of the foregoing, in each case, which is owned or
Controlled by Array.

                                                                    CONFIDENTIAL
                                                    [***] CONFIDENTIAL TREATMENT
                                         HAS BEEN REQUESTED OF REDACTED PORTIONS
<PAGE>

     1.3 "Collaboration Compound" shall mean any Lead Compound, or any
Derivative Compound that has been selected by Takeda for further development.

     1.4 "Collaboration Technology" shall mean (i) all information, data,
know-how, patents and patent applications the subject of which is an invention
conceived and reduced to practice solely or jointly by Array and/or Takeda
personnel in the course of performing, or in connection with, the Research
Program, including without limitation any such inventions comprising a Compound
or Derivative Compound, or method of use or process for the synthesis thereof or
composition-of-matter containing such Compound or Derivative Compound, and (ii)
any divisions, continuations, continuations-in-part, reissues, reexaminations,
extensions or other governmental actions which extend any of the subject matter
of the patent applications or patents in (i) above, and any substitutions,
confirmations, registrations or revalidations of any of the foregoing.

     1.5 "Compound" means a chemical entity synthesized by or on behalf of Array
and delivered to Takeda in the course of the Research Program.

     1.6 "Consumer Price Index" or "CPI" means the Consumer Price Index, All
Urban Consumers, as published by the U.S. Bureau of Labor Statistics.

     1.7 "Control," "Controls" or "Controlled" means possession of the ability
to grant licenses or sublicenses to the other party hereto (other than by virtue
of this Agreement and the licenses granted herein), without violating the terms
of any agreement or other arrangement with, or the rights of, any Third Party.

     1.8 "Derivative Compound" shall mean any chemical entity made by or on
behalf of Takeda which:

          (a) results from a chemical synthesis program based on one or more
     Compounds;

          (b) is based on structure-activity data relating to a Compound in the
     Field; or

          (c) is covered by the claims of any patent application or patent filed
     by Takeda, in accordance with Section 6.2(a) and 6.2(b) below, which patent
     application or patent discloses any compound in subsection (a), or (b)
     above.

"Derivative Compound" also includes any compound made based on, derived from, or
related to another Derivative Compound in any way set forth in subsections (a),
(b) or (c) above.

          1.9 "Extension Period" shall have the meaning set forth in Section
     2.4.

                                  -2-                               CONFIDENTIAL
                                                    [***] CONFIDENTIAL TREATMENT
                                         HAS BEEN REQUESTED OF REDACTED PORTIONS
<PAGE>

     1.10 "Field" shall mean the discovery, and development of small molecule
therapeutics for the treatment [***] in humans through the use of a compound,
the mechanism of action of which is [***].

     1.11 "FTE" shall mean a full-time person dedicated to the Research Program,
or in the case of less than a full-time dedicated person, a full-time,
equivalent person year, based upon a total of one thousand eight hundred eighty
(1,880) hours per year of work in connection with the Research Program.

     1.12 "Initial Term" shall mean the period commencing on the Effective Date
and [***].

     1.13 "Lead Compound" shall mean any Compound which demonstrates activity in
the Field in accordance with the criteria set forth on Exhibit 1.

     1.14 "Lead Product" shall mean any therapeutic or prophylactic product for
use in the Field, incorporating as an active ingredient a Lead Compound without
any covalent modification.

     1.15 "Net Sales" shall mean the gross invoice price by Takeda or its
Affiliates or licensees, as the case may be, for all Lead Products sold by
Takeda, its Affiliates or licensees ("Selling Party"), under this Agreement in
arm's length sales to Third Parties less reasonable deductions allowed to the
Third Party customer by the Selling Party to the extent actually taken by such
Third Party customer, on such sales for: (a) trade, quantity, and cash
discounts; (b) credits, rebates (including those to managed-care entities and
government agencies), and allowances or credits to customers on account of
rejection or returns (including, but not limited to, wholesaler and retailer
returns) or on account of retroactive price reductions affecting such Product;
(c) freight, postage and duties; (d) sales and excise taxes, other consumption
taxes, customs duties and compulsory payments to governmental authorities and
any other governmental charges imposed upon the sale of such Lead Product to
Third Parties and (e) any other deductions to the extent actually taken by such
Third Party customer. Notwithstanding the foregoing, Net Sales shall not include
sales among Takeda, its Affiliates and licensees for resale, provided that such
resale shall be included within Net Sales.

     1.16 "Product" shall mean any therapeutic or prophylactic product for use
in the Field, incorporating as an active ingredient a Collaboration Compound.

     1.17 "Research Program" shall mean the research activities undertaken by
the parties pursuant to Article 2 below.

     1.18 "Research Plan" shall mean the written research plan governing the
effort of the parties in conducting the Research Program, which may be amended,
from time to time by the parties, as they deem necessary or appropriate. The
initial Research Plan is attached hereto as Exhibit 2.

                                  -3-                               CONFIDENTIAL
                                                    [***] CONFIDENTIAL TREATMENT
                                         HAS BEEN REQUESTED OF REDACTED PORTIONS

<PAGE>

     1.19 "Research Term" shall mean the term of the Research Program, as
provided in Section 2.4 below.

     1.20 "SAR Information" shall mean information relating to the relationship
between the biological activity of a chemical entity and its molecular
structure.

     1.21 "Scaffold" shall mean a core chemical structure, synthesized by a
conserved chemistry process.

     1.22 "Takeda Technology" shall mean (i) all information, data, know-how,
patents and patent applications that claim an invention comprising Takeda's
Scaffolds or other chemical techniques that are necessary to conduct the
Research Program, and (ii) any divisions, continuations, continuations-in-part,
reissues, reexaminations, or extensions, thereof and any substitutions,
confirmations or registrations of any of the foregoing, in each case, which is
owned or Controlled by Takeda.

     1.23 "Third Party" shall mean any person or entity other than Array and
Takeda, and their respective Affiliates.

     2. RESEARCH PROGRAM

     2.1 Goal. The goal of the Research Program is the generation of Compounds
and the identification of Lead Compounds within the Field.

     2.2 Research Plan. The Research Plan specifies the Array personnel to
conduct activities with respect to the Research Program. If Array desires to
change some Array personnel, alternative personnel shall be proposed by Array
and approved by Takeda, such approval not to be unreasonably withheld. Takeda
shall have the option, at its own expense, to interview such proposed personnel;
provided, however, that Takeda shall use diligent efforts to conduct such
interviews as expeditiously as possible to avoid delay of the Research Program.
The Research Plan may be modified as mutually agreed by Array and Takeda.

     2.3 Research Program Activities. Subject to the terms and conditions set
forth herein, the parties agree to conduct research under the Research Plan.
During the Research Term, Array and Takeda shall each use their commercially
diligent efforts to identify Lead Compounds in accordance with the Research
Plan.

          (a) Array Responsibilities. Array shall use reasonable efforts to
     perform the Research Program, in view of the Array personnel resources to
     be devoted to the Research Program in accordance with the Research Plan,
     with the goal of generating Compounds from the Scaffolds and/or the
     screening results of Compounds fed back from Takeda which may be
     antagonists against [***], and providing necessary amount of such
     Compounds, together with related information including without limitation,
     structural information to Takeda for screening in order to

                                  -4-                               CONFIDENTIAL
                                                    [***] CONFIDENTIAL TREATMENT
                                         HAS BEEN REQUESTED OF REDACTED PORTIONS
<PAGE>

     identify Lead Compounds in accordance with the Research Plan. Array shall
     purify each synthesized Compound to at least [***] purity, as analyzed by
     liquid chromatography-mass spectroscopy, and to provide Takeda with at
     least [***] of each Compound to enable Takeda to conduct its activities
     under the Research Plan. Risk of loss for and title to the Compounds
     provided by Array to Takeda under this Agreement shall pass from Array to
     Takeda upon delivery by Array to the shipping agent in the United States
     designated by Takeda. During the Research Program, Array will provide [***]
     FTEs to conduct the Research Program, or such greater number as the parties
     may agree.

          (b) Takeda Responsibilities. Takeda shall use reasonable efforts to
     promptly screen Compounds provided by Array against the [***]. In addition,
     Takeda shall provide Array with such support and assistance as Array may
     reasonably request, including without limitation, providing Array with SAR
     Information and other Takeda Technology.

          (c) Takeda Participation. During the term of the Research Program,
     each party shall keep the other informed of its activities in the Field.
     The parties shall meet in person at least quarterly at mutually agreed
     locations, with Array's travel, accommodation and other expenses actually
     incurred for such meetings to be reimbursed by Takeda [***]. It is
     understood that the conduct of the Research Program will take place
     primarily at Array's facilities. To ensure participation by Takeda, the
     parties' respective personnel shall hold at least bi-weekly project
     meetings, in person or by telephone or videoconference, to exchange
     information with respect to the Research Program. [***] during the term of
     the Agreement and subject to Array's approval (with such approval not
     unreasonably withheld), upon fifteen (15) days written notice to Array,
     [***].

     2.4 Extension of Research Program Term.

          (a) Option to Extend. Takeda shall have the right to extend the term
     of the Research Program for up to [***] successive [***] terms beyond the
     Initial Term (each an "Extension Period"). To exercise such option, Takeda
     shall so notify Array in writing at least ninety (90) days prior to the end
     of the Initial Term or the first Extension Period, whichever is applicable
     and then, Array and Takeda shall negotiate for the amendment of the
     Research Plan.

          (b) Extension Terms. During each Extension Period, Takeda shall
     continue to fund the same number of Array FTEs conducting activities under
     the amended Research Program as Takeda funded at the end of the Initial
     Term or first Extension Period, whichever is applicable or such other
     greater number as the parties may agree.

     2.5 Identification of Lead Compounds.

          (a) General. The parties have established that a chemical entity,
     which meets the guidelines set forth in Exhibit 1, shall be deemed a Lead
     Compound. Takeda shall promptly notify Array of the identification from the
     Compounds of any Lead Compound.

                                  -5-                               CONFIDENTIAL
                                                    [***] CONFIDENTIAL TREATMENT
                                         HAS BEEN REQUESTED OF REDACTED PORTIONS

<PAGE>

     2.6 Exclusivity. Except as set forth herein, during the Initial Term, any
Extension Periods and for [***] afterwards, Array shall not, without Takeda's
consent, conduct, participate in, or fund, directly or indirectly, alone or with
an Affiliate or a Third Party, compound discovery research specifically directed
to the Field, except pursuant to the Agreement.

     2.7 Substitute Targets. If, during the Initial Term or any Extension
Periods, Takeda determines there is insufficient progress toward identification
of Lead Compounds in the Field, Takeda may propose, under a separate
confidentiality agreement, a substitute target against which Takeda may screen
the Compounds without paying any additional consideration. Within [***] days
after receipt of Takeda's proposal, Array shall notify Takeda whether such
substitute target may be pursued without a conflict with or breach of Array's
existing agreements with Third Parties and that Array agrees to pursue such
substitute target. Upon Takeda's receipt of Array's agreement to pursue such
substitute target, (i) so much of the first sentence of Section 1.10 as reads
[***] shall be replaced by the disease state and the identity of the substitute
target, respectively. In the event that Array cannot pursue such substitute
target proposed by Takeda, then Takeda shall propose another substitute target
under this Section 2.7.

     2.8 Records; Inspection. Array and Takeda shall maintain records of the
Research Program (or cause such records to be maintained) in sufficient detail
and in good scientific manner as will properly reflect all work done and results
achieved in the performance of the Research Program (including all data in the
form required under any applicable governmental regulations).

     3. LICENSES; OPTION

     3.1 License to Takeda.

          (a) Research License. Subject to the terms and conditions of this
     Agreement, Array agrees to grant and hereby grants to Takeda under Array's
     Technology and Array's interest in Collaboration Technology, a
     non-exclusive, non-transferable, non-sublicensable, royalty-free license,
     without the right to grant sublicenses, solely to conduct the Research
     Program.

          (b) Further Activity. Array hereby grants to Takeda under Array's
     interest in Collaboration Technology, a non-exclusive, royalty-free
     license, without the right to grant and authorize sublicenses, to exploit
     the same for purposes inside and outside the Field. Notwithstanding the
     foregoing, Takeda shall have the right to grant sublicenses for the
     purposes of making, or having made Compounds and/or Derivative Compounds.

     3.2 Licenses to Array.

          (a) Research License. Subject to the terms and conditions of this
     Agreement, Takeda agrees to grant and hereby grants to Array under Takeda
     Technology and Takeda's interest in Collaboration Technology, a
     non-exclusive, non-transferable, non-sublicensable, royalty-free license,
     without the right to grant sublicenses, solely to conduct the Research
     Program.

                                  -6-                               CONFIDENTIAL
                                                    [***] CONFIDENTIAL TREATMENT
                                         HAS BEEN REQUESTED OF REDACTED PORTIONS

<PAGE>

          (b) Activities Outside Field. Takeda hereby grants to Array under
     Takeda's interest in Collaboration Technology, a non-exclusive,
     royalty-free license, with the right to grant and authorize sublicenses, to
     exploit the same for purposes outside the Field, provided however, that
     such license shall not extend to the composition of matter and the method
     of use of any Compounds and/or Derivative Compounds.

     3.3 No Implied Licenses. Only the licenses granted pursuant to the express
terms of this Agreement shall be of any legal force or effect. No other license
rights shall be created by implication, estoppel or otherwise.

     4. PAYMENTS

     4.1 Research Program Funding.

          (a) Research Phase Payment Schedule. Takeda agrees to pay Array
     research funding for the conduct of the Research Program in an amount equal
     to the number of Array FTE's called for in the Research Plan for the
     applicable year multiplied by the Array FTE Rate (as defined below). The
     parties may mutually agree to increase the number of Array FTE's at any
     time. Such payments shall be paid in quarterly installments in advance. In
     the event that the parties agree to increase the number of FTEs prior to
     the end of a quarter, then for such quarter Takeda shall make payment to
     Array for such additional FTEs at the end of such quarter; provided that,
     for subsequent quarters, Takeda shall make payment for such additional FTEs
     in advance. Array shall submit an invoice to Takeda at least [***] days
     before the time each payment is due. The initial payment shall be made
     within [***] days after the Effective Date, and subsequent payments shall
     be made on or before each date quarterly thereafter. Such payments are
     non-creditable and non-refundable.

          (b) FTE Rate. The Array FTE Rate shall be equal to [***] per FTE per
     year. Effective [***], the FTE Rate shall increase by the percentage
     increase, if any, in the Consumer Price Index for all Urban Consumers, as
     published by the U.S. Department of Labor, Bureau of Statistics, since the
     Effective Date or the last adjustment hereunder, whichever is later.

          (c) Non-FTE Costs. Takeda shall reimburse Array for the actual cost of
     chemicals, chemical reagents and related materials necessary or useful for
     conduct of the Research Program, where such materials cost more than [***]
     total per one order, provided, however, that Array obtains Takeda's
     approval prior to incurring any such expense. Array shall submit invoices
     for such materials on a monthly basis, and Takeda shall pay each such
     invoice within [***] days of receipt thereof. In addition, Takeda shall
     reimburse any out-of-pocket expenses incurred by Array in connection with
     the Research Program; provided, however, that Array obtains Takeda's
     approval prior to incurring any such expense.

          (d) No Withholding. All amounts paid to Array pursuant to this Section
     4.1 shall be made without withholding for taxes or any other charges.

                                  -7-                               CONFIDENTIAL
                                                    [***] CONFIDENTIAL TREATMENT
                                         HAS BEEN REQUESTED OF REDACTED PORTIONS

<PAGE>

     4.2 Research and Development Milestones. Takeda shall pay to Array the
following amounts within [***] days following the achievement of each occurrence
of the following milestones in the Field:

<TABLE>
<CAPTION>
         RESEARCH AND DEVELOPMENT MILESTONES                       AMOUNT
         -----------------------------------                       ------
<S>                                                                <C>
         1. [***]                                                  [***]

         2. [***]                                                  [***]

         3. [***]                                                  [***]
</TABLE>

     For purposes of this Section 4.2: (i) Takeda shall not be required to pay
Milestone 1 for a Collaboration Compound that is not chemically distinct from a
Collaboration Compound for which Milestone 1 has been paid; (ii) in any event
Milestone 1 shall not be payable more than [***] times even if more than [***]
chemically distinct Collaboration Compounds are identified; and (iii) clinical
trial shall be deemed initiated upon the first dosing of the first patient in
such trial.

It is understood, that Milestones 2 and 3 shall be paid [***].

     4.3 Royalties. Takeda shall pay Array a running royalty of [***] on Net
Sales of each Lead Product sold by or under authority of Takeda, its Affiliates
or licensees.

     4.4 Royalty Term. The obligation of Takeda to pay royalties under Section
4.3 above shall continue on a Lead Product-by-Lead Product and
country-by-country basis until the earlier of (i) the expiration of the last
issued patent covering the composition of a Lead Product in such country or (ii)
[***] after the date of the first commercial sale of such Lead Product in such
country.

     5. PAYMENTS; BOOKS AND RECORDS

     5.1 Payment Method. All payments under this Agreement shall be made by bank
wire transfer in immediately available funds to an account designated by Array.
All dollar amounts specified in this Agreement, and all payments made hereunder,
are and shall be made in U.S. dollars. Any payments due under this Agreement
which are not paid by the date such payments are due under this Agreement shall
bear interest to the extent permitted by applicable law at the U.S. prime rate
per annum quoted in the "Money Rates" column of The Wall Street Journal (U.S.,
Western Edition) on the first business day after such payment is due, plus an
additional two percentage points (2%), calculated on the number of days such
payment is delinquent. This Section 5.1 shall in no way limit any other remedies
available to either party.

                                  -8-                               CONFIDENTIAL
                                                    [***] CONFIDENTIAL TREATMENT
                                         HAS BEEN REQUESTED OF REDACTED PORTIONS

<PAGE>

     5.2 Currency Conversion. If any currency conversion shall be required in
connection with the calculation of amounts payable hereunder, such conversion
shall be made using the average of the buying and selling exchange rate for
conversion of the foreign currency in U.S. dollars, quoted for current
transactions reported in The Wall Street Journal (U.S., Western Edition) for the
last business day of the calendar quarter to which such payment pertains.

     5.3 Taxes.

          (a) Generally. Each party shall bear and, except as otherwise
     expressly provided in this Section 5.3, pay any and all taxes, duties,
     levies, and other similar charges (and any related interest and penalties),
     however designated, imposed on that party as a result of the existence or
     operation of this Agreement. If laws or regulations require that taxes be
     withheld, the paying party will (i) deduct those taxes from the remittable
     payment, (ii) timely pay the taxes to the proper taxing authority, and
     (iii) send proof of payment to the other party within sixty (60) days
     following that payment.

          (b) Certain Payments. Notwithstanding Section 5.3(a) above, all
     payments by Takeda specified in Article 4 above are expressed as net
     amounts and shall be made free and clear of, and without reduction for, any
     withholding taxes. Any such taxes, which are otherwise imposed on payments
     to Array, shall be the sole responsibility of Takeda. Takeda shall provide
     Array with official receipts issued by the appropriate taxing authority or
     such other evidence as is reasonably requested by Array to establish that
     such taxes have been paid. Takeda may provide written notice to Array of
     any foreign tax credits that may be available for use by Array to offset
     any withholding taxes paid by Takeda under this Agreement, and upon any
     such notification, Array shall use its best efforts, at Takeda's expense,
     to obtain such foreign tax credit. If Array uses a foreign tax credit
     received by Array as a result of the payment of withholding taxes by Takeda
     and thereby reduces the amount of U.S. income tax that Array otherwise
     would have paid, Array shall refund to Takeda the amount of such reduction
     with respect to such foreign tax credit.

     5.4 Royalties.

          (a) Quarterly Reports. Beginning with the first quarter in which a
     sale of a Lead Product occurs, Takeda shall make quarterly reports to Array
     within sixty (60) days after the end of each calendar quarter, setting
     forth in reasonable detail, a calculation of any Net Sales in such quarter.
     Concurrently with making such report, Takeda shall remit payment to Array
     for any royalty due under Section 4.3 above.

          (b) Records; Inspection. Takeda shall keep, and require its Affiliates
     and licensees to keep, complete, true and accurate books of accounts and
     records for the purpose of determining payments due pursuant to Section 4.3
     of this Agreement, if any. Such books and records shall be kept for at
     least five (5) years following the end of the calendar quarter to which
     they pertain. Such records will be open for inspection at the principal
     place of business of Takeda during such five (5) year period by an
     independent auditor chosen by Array and reasonably acceptable to

                                  -9-                               CONFIDENTIAL
                                                    [***] CONFIDENTIAL TREATMENT
                                         HAS BEEN REQUESTED OF REDACTED PORTIONS

<PAGE>

     Takeda for the purpose of verifying the amounts payable by Array hereunder.
     Such inspections may be made no more than once each calendar year, at
     reasonable times and on reasonable notice. Array's independent auditor
     shall be obligated to execute a reasonable confidentiality agreement prior
     to commencing any such inspection and shall inform Array only of the
     accuracy of payments due pursuant to Section 4.3. Inspections conducted
     under this Section 5.4 shall be at the expense of Array, unless a variation
     or error producing an underpayment in amounts payable exceeding ten percent
     (10%) of the amount paid for the period covered by the inspection is
     established in the course of any such inspection, whereupon all costs
     relating to the inspection for such period and any underpaid amounts that
     are discovered will be paid by Takeda, together with interest on such
     underpaid amounts at the rate set forth in Section 5.1 above. The parties
     will endeavor to minimize disruption of Takeda's normal business activities
     to the extent reasonably practicable.

     6. INTELLECTUAL PROPERTY

     6.1 Ownership of Inventions; Disclosure.

          (a) General. Subject to Section 6.1(b) below, title to all inventions
     and other intellectual property made by employees of Array in the course of
     performing, or in connection with, the Research Program shall be owned by
     Array; title to all inventions and other intellectual property made by
     employees of Takeda in the course of performing, or in connection with, the
     Research Program shall be owned by Takeda; title to all inventions and
     other intellectual property made jointly by employees of Takeda and Array
     in the course of performing, or in connection with, the Research Program
     shall be deemed jointly owned by Takeda and Array. Inventorship of
     inventions and other intellectual property conceived and/or reduced to
     practice pursuant to this Agreement shall be determined in accordance with
     the patent laws of the United States.

          (b) Notwithstanding Section 6.1(a) above, all compositions of matter
     within the Collaboration Technology made by Array employees (solely or
     jointly with Takeda), comprising Compounds and/or Lead Compounds, and all
     methods of use thereof, within or outside the Field, shall be solely owned
     by Takeda, and Array hereby assigns all of its rights therein to Takeda. In
     addition, all compositions of matter within the Collaboration Technology
     made by Array employees (solely or jointly with Takeda) that fall within
     the scope of a patent claim that covers a Lead Compound shall be solely
     owned by Takeda, whether or not such compositions of matter have been
     synthesized in the course of the Research Program, and Array hereby assigns
     all of its rights therein to Takeda. Nothing herein shall prevent Takeda
     from filing a patent or patent application claiming a composition of
     matter, or method of use thereof, on any invention made solely by Takeda,
     whether or not such compositions of matter have not been synthesized in the
     course of the Research Program.

     6.2 Patent Prosecution.

          (a) Jointly-Owned Inventions. Takeda shall have the first right to
     control the preparation, filing, prosecution and maintenance of patent
     applications and patents directed to jointly-owned Collaboration
     Technology, and conducting any interferences, re-examinations,

                                 -10-                               CONFIDENTIAL
                                                    [***] CONFIDENTIAL TREATMENT
                                         HAS BEEN REQUESTED OF REDACTED PORTIONS

<PAGE>
     reissues and oppositions with respect thereto. Except as provided in this
     Agreement, neither party shall have an obligation to account to the other,
     or obtain the consent of the other, with respect to the exploitation
     (directly or through licensees of third parties) of any jointly-owned
     invention or intellectual property right, and each party hereby waives any
     right it may have under the laws of any jurisdiction to require such an
     accounting or consent.

          (b) Solely-Owned Inventions. Each party shall be responsible, at its
     expense and in its sole discretion, for preparing, filing, prosecuting and
     maintaining, in such countries as it deems appropriate, any and all patent
     applications and patents directed to inventions solely owned by such party
     pursuant to Section 6.1 above, and conducting any interferences,
     re-examinations, reissues and oppositions with respect to such patent
     applications and patents.

     6.3 Cooperation. Takeda and Array shall each reasonably cooperate with and
assist the other at its own expense in connection with such activities, at the
other party's request, including without limitation by making scientists and
scientific records reasonably available to the prosecuting party.

     7. CONFIDENTIALITY

     7.1 Confidential Information. Except as expressly provided herein, the
receiving party (hereinafter, the "Receiving Party") shall not disclose to any
third party or use for any purpose any Confidential Information furnished to it
by the other party (hereinafter the "Disclosing Party") pursuant to this
Agreement. For purposes of this Article 7, "Confidential Information" shall mean
any information disclosed by the Disclosing Party to the Receiving Party which
if disclosed in tangible form is marked "confidential" or with other similar
designation to indicate its confidential or proprietary nature or if disclosed
orally is indicated orally to be confidential or proprietary by the Disclosing
Party at the time of such disclosure and is confirmed in writing as confidential
or proprietary by the Disclosing Party within forty-five (45) days after such
disclosure. Notwithstanding the foregoing, Confidential Information shall not
include any information that, in each case as demonstrated by written
documentation: (i) was already known to the Receiving Party, other than under an
obligation of confidentiality, at the time of disclosure; (ii) was generally
available to the public or otherwise part of the public domain at the time of
its disclosure to the Receiving Party; (iii) became generally available to the
public or otherwise part of the public domain after its disclosure and other
than through any act or omission of the Receiving Party in breach of this
Agreement; (iv) was subsequently lawfully disclosed to the Receiving Party by a
third party who did not acquire it directly or indirectly from the Disclosing
Party; or (v) was developed by the Receiving Party without use of or reference
to any Confidential Information of the Disclosing Party.

     7.2 Permitted Use and Disclosures. The Receiving Party may use and disclose
the Confidential Information of the Disclosing Party to the extent necessary to
exercise its rights or perform its obligations under this Agreement, in filing
or prosecuting applications and patents, prosecuting or defending litigation,
complying with applicable governmental regulations or court order or otherwise
submitting information to tax or other governmental authorities, conducting
trials,

                                 -11-                               CONFIDENTIAL
                                                    [***] CONFIDENTIAL TREATMENT
                                         HAS BEEN REQUESTED OF REDACTED PORTIONS

<PAGE>
or making a permitted sublicense or otherwise exercising license rights
expressly granted to the other party to it pursuant to the terms of this
Agreement, provided that if the Receiving Party is required to make any such
disclosures of the Disclosing Party's Confidential Information, other than
pursuant to a confidentiality agreement it shall give reasonable advance notice
the Disclosing Party of such disclosure and, save to the extent inappropriate in
the case of patent applications, shall use its reasonable efforts to secure
confidential treatment of such Confidential Information in consultation with the
Disclosing Party prior to its disclosure (whether through protective orders or
otherwise) and disclosure only that portion of the Confidential Information
necessary to comply with such requirements.

     7.3 Termination of Prior Agreement. This Agreement supersedes the
Confidentiality Agreement between the Parties dated January 22, 2001. All
information exchanged between the Parties under that Agreement shall be deemed
Confidential Information and shall be subject to the terms of this Article 7.

     7.4 Nondisclosure of Terms. Each of the parties hereto agrees not to
disclose to any third party the terms of this Agreement without the prior
written consent of the other party hereto, except to such party's attorneys,
advisors, investors and others on a need to know basis under circumstances that
reasonably ensure the confidentiality thereof, or to the extent required by law.
Notwithstanding the foregoing, the parties shall agree upon a press release to
announce the execution of this Agreement; thereafter, Array and Takeda may each
disclose to third parties the information contained in such press release
without the need for further approval by the other.

     8. REPRESENTATIONS AND WARRANTIES

     8.1 Takeda. Takeda represents and warrants on its own behalf and on behalf
of its Affiliates that: (i) it has the legal power, authority and right to enter
into this Agreement and to perform all of its obligations hereunder; (ii) this
Agreement is a legal and valid obligation binding upon it and enforceable in
accordance with its terms; (iii) it has the full right to enter into this
Agreement, and to fully perform its obligations hereunder; (iv) it has not
previously granted, and during the term of this Agreement will not knowingly
make any commitment or grant any rights which are in conflict in any material
way with the rights and licenses granted herein; (v) it shall conduct the
Research Program with highly professional standards and in accordance with the
Research Plan and all applicable laws; and (vi) it is not , as of the Effective
Date, aware of any third party claims or legal proceedings, potential or
otherwise, relating to the Takeda Technology..

     8.2 Array. Array represents and warrants that: (i) it has the legal right
and power to extend the rights granted in this Agreement; (ii) this Agreement is
a legal and valid obligation binding upon it and enforceable in accordance with
its terms; (iii) it has the full right to enter into this Agreement, and to
fully perform its obligations hereunder; (iv) it has not previously granted, and
during the term of this Agreement will not knowingly make any commitment or
grant any rights which are in conflict in any material way with the rights and
licenses granted herein; (v) it shall conduct the Research Program with highly
professional standards and in accordance with the

                                 -12-                               CONFIDENTIAL
                                                    [***] CONFIDENTIAL TREATMENT
                                         HAS BEEN REQUESTED OF REDACTED PORTIONS

<PAGE>
Research Plan and all applicable laws; and (vi) it is not , as of the Effective
Date, aware of any third party claims or legal proceedings, potential or
otherwise, relating to the Array Technology.

     8.3 Disclaimer. Takeda and Array specifically disclaim any guarantee that
the Research Program will be successful, in whole or in part. The failure of the
parties to successfully develop Lead Compounds or Products will not constitute a
breach of any representation or warranty or other obligation under this
Agreement. EXCEPT AS OTHERWISE EXPRESSLY SET FORTH IN THIS AGREEMENT, ARRAY AND
TAKEDA MAKE NO REPRESENTATIONS AND EXTEND NO WARRANTIES OR CONDITIONS OF ANY
KIND, EITHER EXPRESS OR IMPLIED, WITH RESPECT TO THE COLLABORATION TECHNOLOGY,
TAKEDA TECHNOLOGY, COMPOUNDS, LEAD COMPOUNDS, DERIVATIVE COMPOUNDS, INFORMATION
DISCLOSED HEREUNDER OR PRODUCTS INCLUDING, BUT NOT LIMITED TO, WARRANTIES OF
MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, VALIDITY OF ANY ARRAY
TECHNOLOGY, TAKEDA TECHNOLOGY OR COLLABORATION TECHNOLOGY, PATENTED OR
UNPATENTED, OR NONINFRINGEMENT OF THE INTELLECTUAL PROPERTY RIGHTS OF THIRD
PARTIES.

     9. INDEMNIFICATION

     9.1 Takeda. Takeda agrees to indemnify, defend and hold Array and its
Affiliates and their respective directors, officers, employees, agents and their
respective successors, heirs and assigns (the "Array Indemnitees") harmless from
and against any losses, costs, claims, damages, liabilities or expense
(including reasonable attorneys' and professional fees and other expenses of
litigation) (collectively, "Liabilities") arising, directly or indirectly out of
or in connection with Third Party claims, suits, actions, demands or judgments,
relating to (i) any Compounds, Derivative Compounds or Products manufactured,
used, sold or otherwise distributed by or under authority of Takeda following
the Research Program (including product liability claims), or (ii) any breach by
Takeda of the representations and warranties made in this Agreement, except, in
each case, to the extent such Liabilities result from a material breach of this
Agreement by Array, negligence or intentional misconduct of Array.

     9.2 Array. Array agrees to indemnify, defend and hold Takeda and its
Affiliates and their respective directors, officers, employees, agents and their
respective heirs and assigns (the "Takeda Indemnitees") harmless from and
against any losses, costs, claims, damages, liabilities or expense (including
reasonable attorneys' and professional fees and other expenses of litigation)
(collectively, "Liabilities") arising, directly or indirectly out of or in
connection with Third Party claims, suits, actions, demands or judgments,
relating to any breach by Array of its representations and warranties made in
this Agreement, except, in each case, to the extent such Liabilities result from
a material breach of this Agreement by Takeda, negligence or intentional
misconduct of Takeda.

     9.3 Procedure. In the event that any Indemnitee (either a Takeda Indemnitee
or an Array Indemnitee) intends to claim indemnification under this Article 9,
it shall promptly notify the

                                 -13-                               CONFIDENTIAL
                                                    [***] CONFIDENTIAL TREATMENT
                                         HAS BEEN REQUESTED OF REDACTED PORTIONS
<PAGE>

other party in writing of such alleged Liability. The indemnifying party shall
have the right to control the defense thereof with counsel of its choice as long
as such counsel is reasonably acceptable to Indemnitee; provided, however, that
any Indemnitee shall have the right to retain its own counsel at its own
expense, for any reason, including if representation of any Indemnitee by the
counsel retained by the indemnifying party would be inappropriate due to actual
or potential differing interests between such Indemnitee and any other party
reasonably represented by such counsel in such proceeding. The affected
Indemnitee shall cooperate with the indemnifying party and its legal
representatives in the investigation of any action, claim or liability covered
by this Article 9. The Indemnitee shall not, except at its own cost, voluntarily
make any payment or incur any expense with respect to any claim or suit without
the prior written consent of the indemnifying party, which such party shall not
be required to give.

     10. TERM AND TERMINATION

     10.1 Term. The term of this Agreement shall commence on the Effective Date,
and shall continue in full force and effect until the date no further payments
are due under Section 4.4, unless terminated earlier as provided in this Article
10.

     10.2 Termination for Breach. Either party to this Agreement may terminate
the Research Program and this Agreement in the event the other party hereto
shall have materially breached or defaulted in the performance of any of its
material obligations hereunder, and such default shall have continued for [***]
days after written notice thereof was provided to the breaching party by the
non-breaching party. Any termination shall become effective at the end of such
[***] day period unless the breaching party (or any other party on its behalf)
has cured any such breach or default prior to the expiration of the [***] day
period; provided, however, in the case of a failure to pay any amount due
hereunder, such default may be the basis of termination [***] business days
following the date that notice of such default was provided to the breaching
party.

     10.3 Termination for Insolvency. If voluntary or involuntary proceedings by
or against a party are instituted in bankruptcy under any insolvency law, or a
receiver or custodian is appointed for such party, or proceedings are instituted
by or against such party for corporate reorganization, dissolution, liquidation
or winding-up of such party, which proceedings, if involuntary, shall not have
been dismissed within sixty (60) days after the date of filing, or if such party
makes an assignment for the benefit of creditors, or substantially all of the
assets of such party are seized or attached and not released within sixty (60)
days thereafter, the other party may immediately terminate the Research Program
and/or this Agreement, effective upon notice of such termination.

     10.4 Permissive Termination. Takeda may, at any time and without any
specific cause, [***] prior notice to Array provided that such notice shall
[***] of the Effective Date.

                                 -14-                               CONFIDENTIAL
                                                    [***] CONFIDENTIAL TREATMENT
                                         HAS BEEN REQUESTED OF REDACTED PORTIONS

<PAGE>

     10.5 Return of Materials. Upon any termination of this Agreement, Takeda
and Array shall promptly return to the other all Confidential Information
received from the other party, except one copy of which may be retained for
archival purposes.

     10.6 Effect of Breach or Termination.

          (a) Accrued Rights and Obligations. Termination of this Agreement for
     any reason shall not release either party hereto from any liability which,
     at the time of such termination, has already accrued to the other party or
     which is attributable to a period prior to such termination nor preclude
     either party from pursuing any rights and remedies it may have hereunder or
     at law or in equity with respect to any breach of this Agreement.

     10.7 Survival Sections.

          (a) Articles 1, 6, 7, 9 and 11 and 5.4 of this Agreement, shall
     survive the expiration or termination of this Agreement for any reason.

          (b) In the event of termination by Array under Section 10.2 or 10.3,
     Sections 3.2(b), 4.2, 4.3 and 4.4 shall survive such termination in
     addition to above Articles, and Takeda shall assign back to Array all the
     right, title and interest in and to Collaboration Technology assigned to
     Takeda under Section 6.1(b), which thereafter shall be treated pursuant to
     Section 6.1(a).

          (c) In the event of termination by Takeda under Section 10.2 or 10.3,
     Section 3.1(b), 4.2, 4.3, and 4.4 shall survive such termination in
     addition to above Articles.

          (d) In the event of termination by Takeda under Section 10.4 or
     expiration of this Agreement, Sections 3.1(b), 3.2(b), 4.2, 4.3 and 4.4
     shall survive such termination in addition to the above Articles.

     11. MISCELLANEOUS

     11.1 Governing Laws. This Agreement and any dispute arising from the
construction, performance or breach hereof shall be governed by and construed,
and enforced in accordance with, the laws of New York, without reference to
conflicts of laws principles.

     11.2 Waiver. It is agreed that no waiver by either party hereto of any
breach or default of any of the covenants or agreements herein set forth shall
be deemed a waiver as to any subsequent and/or similar breach or default.

     11.3 Assignment. This Agreement shall not be assignable by either party to
a Third Party without the written consent of the other party hereto; except that
either party may assign this Agreement, without such consent, to an entity that
acquires all or substantially all of the business or assets of such party to
which this Agreement pertains (whether by merger, reorganization, acquisition,
sale or otherwise), and agrees in writing to be bound by the terms and
conditions of this
                                 -15-                               CONFIDENTIAL
                                                    [***] CONFIDENTIAL TREATMENT
                                         HAS BEEN REQUESTED OF REDACTED PORTIONS

<PAGE>

Agreement. The terms and conditions shall be binding on and inure to the benefit
of the permitted successors and assigns of the parties.

     11.4 Independent Contractors. The relationship of the parties hereto is
that of independent contractors. The parties hereto are not deemed to be agents,
partners or joint venturers of the others for any purpose as a result of this
Agreement or the transactions contemplated thereby.

     11.5 Compliance with Laws. In exercising their rights under this license,
the parties shall fully comply with the requirements of any and all applicable
laws, regulations, rules and orders of any governmental body having jurisdiction
over the exercise of rights under this license including, without limitation,
those applicable to the discovery, development, manufacture, distribution,
import and export and sale of Products pursuant to this Agreement.

     11.6 Notices. All notices, requests and other communications hereunder
shall be in writing and shall be personally delivered or by registered or
certified mail, return receipt requested, postage prepaid, or by facsimile, in
each case to the respective address specified below, or such other address as
may be specified in writing to the other parties hereto and shall be deemed to
have been given upon receipt:

                  If to Array, to:            Array BioPharma Corporation
                                              1885 33rd Street
                                              Boulder, Colorado, USA  80301
                                              Fax number:  (303) 449-5376

                  with a copy to:             Wilson Sonsini Goodrich & Rosati
                                              650 Page Mill Road
                                              Palo Alto, California  94304-1050
                                              Attn:  Kenneth A. Clark, Esq.
                                              Fax number:  (650) 493-6811

                  If toTakeda, to:            Takeda Chemical Industries, LTD.
                                              Strategic Research Planning
                                              Pharmaceutical Research Division
                                              17-85, Jusohonmachi 2-chome
                                              Yodogawa-ku, Osaka 532-8686
                                              Japan
                                              Attn: [***]
                                              Fax number: +81 6 6300 6834

                  11.7 Severability. If any provision hereof should be held
invalid, illegal or unenforceable in any jurisdiction, the parties shall
negotiate in good faith a valid, legal and enforceable substitute provision that
most nearly reflects the original intent of the parties and all other provisions
hereof shall remain in full force and effect in such jurisdiction and shall be
liberally

                                 -16-                               CONFIDENTIAL
                                                    [***] CONFIDENTIAL TREATMENT
                                         HAS BEEN REQUESTED OF REDACTED PORTIONS

<PAGE>

construed in order to carry out the intentions of the parties hereto as nearly
as may be possible. Such invalidity, illegality or unenforceability shall not
affect he validity, legality or enforceability of such provision in any other
jurisdiction.

     11.8 Advice of Counsel. Array and Takeda have each consulted counsel of
their choice regarding this Agreement, and each acknowledges and agrees that
this Agreement shall not be deemed to have been drafted by one party or another
and will be construed accordingly.

     11.9 Force Majeure. Neither party shall lose any rights hereunder or be
liable to the other party for damages or losses (except for payment obligations)
on account of failure of performance by the defaulting party if the failure is
occasioned by war, strike, fire, Act of God, earthquake, flood, lockout,
embargo, governmental acts or orders or restrictions, failure of suppliers, or
any other reason where failure to perform is beyond the reasonable control and
not caused by the negligence, intentional conduct or misconduct of the
non-performing party and such party has exerted all reasonable efforts to avoid
or remedy such force majeure; provided, however, that in no event shall a party
be required to settle any labor dispute or disturbance.

     11.10 Complete Agreement. This Agreement with its Exhibits, constitutes the
entire agreement, both written and oral, between the parties with respect to the
subject matter hereof, and all prior agreements respecting the subject matter
hereof, either written or oral, express or implied, shall be abrogated,
canceled, and are null and void and of no effect. No amendment or change hereof
or addition hereto shall be effective or binding on either of the parties hereto
unless reduced to writing and executed by the respective duly authorized
representatives of Array and Takeda.

     11.11 Headings. The captions to the several Sections hereof are not a part
of this Agreement, but are included merely for convenience of reference and
shall not affect its meaning or interpretation.

     11.12 Counterparts. This Agreement may be executed in counterparts, each of
which shall be deemed to be an original and all of which together shall be
deemed to be one and the same agreement.

     IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be
duly executed by their authorized representatives and delivered in duplicate
originals as of the Effective Date.

<TABLE>
<CAPTION>
TAKEDA CHEMICAL INDUSTRIES, LTD.                     ARRAY BIOPHARMA INC.
---------------------------------                    -------------------
<S>                                                  <C>

By:                                                           By:
      -----------------------------------------------              ---------------------------------------------------

Name:                                                         Name:
      -----------------------------------------------               --------------------------------------------------

Title:                                                        Title:
       ----------------------------------------------                -------------------------------------------------
</TABLE>

                                 -17-                               CONFIDENTIAL
                                                    [***] CONFIDENTIAL TREATMENT
                                         HAS BEEN REQUESTED OF REDACTED PORTIONS

<PAGE>

                                   EXHIBIT 1.

                                      [***]

   1.   [***].

   2.   [***]

   3.   [***]

   4.   [***]

   5.   [***]

   6.   [***]

                                 -18-                               CONFIDENTIAL
                                                    [***] CONFIDENTIAL TREATMENT
                                         HAS BEEN REQUESTED OF REDACTED PORTIONS

<PAGE>

                                   EXHIBIT 2.

                                  RESEARCH PLAN

         ARRAY PERSONNEL

         The following Array scientist will conduct the Research Program:

         [***]

                                 -19-                               CONFIDENTIAL
                                                    [***] CONFIDENTIAL TREATMENT
                                         HAS BEEN REQUESTED OF REDACTED PORTIONS

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00031-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00031-of-00352.parquet"}]]